BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 32647050)

  • 1. Long-term Cost-Effectiveness of Dexcom G6 Real-time Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Patients With Type 1 Diabetes in the U.K.
    Roze S; Isitt J; Smith-Palmer J; Javanbakht M; Lynch P
    Diabetes Care; 2020 Oct; 43(10):2411-2417. PubMed ID: 32647050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term cost-effectiveness of Dexcom G6 real-time continuous glucose monitoring system in people with type 1 diabetes in Australia.
    Isitt JJ; Roze S; Tilden D; Arora N; Palmer AJ; Jones T; Rentoul D; Lynch P
    Diabet Med; 2022 Jul; 39(7):e14831. PubMed ID: 35298036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Cost-Effectiveness the Dexcom G6 Real-Time Continuous Glucose Monitoring System Compared with Self-Monitoring of Blood Glucose in People with Type 1 Diabetes in France.
    Roze S; Isitt JJ; Smith-Palmer J; Lynch P; Klinkenbijl B; Zammit G; Benhamou PY
    Diabetes Ther; 2021 Jan; 12(1):235-246. PubMed ID: 33165838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the Long-Term Cost-Effectiveness of the Dexcom G6 Continuous Glucose Monitor versus Self-Monitoring of Blood Glucose in People with Type 1 Diabetes in Canada.
    Roze S; Isitt JJ; Smith-Palmer J; Lynch P
    Clinicoecon Outcomes Res; 2021; 13():717-725. PubMed ID: 34408456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-utility of real-time continuous glucose monitoring versus self-monitoring of blood glucose in people with insulin-treated Type II diabetes in France.
    Alshannaq H; Pollock RF; Joubert M; Ahmed W; Norman GJ; Lynch PM; Roze S
    J Comp Eff Res; 2024 Mar; 13(3):e230174. PubMed ID: 38294332
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-utility of real-time continuous glucose monitoring versus self-monitoring of blood glucose and intermittently scanned continuous glucose monitoring in people with type 1 diabetes receiving multiple daily insulin injections in Denmark.
    Alshannaq H; Cogswell G; Pollock RF; Ahmed W; Norman GJ; Lynch PM; Roze S
    Diabetes Obes Metab; 2023 Sep; 25(9):2704-2713. PubMed ID: 37334522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of Continuous Glucose Monitoring for Adults With Type 1 Diabetes Compared With Self-Monitoring of Blood Glucose: The DIAMOND Randomized Trial.
    Wan W; Skandari MR; Minc A; Nathan AG; Winn A; Zarei P; O'Grady M; Huang ES
    Diabetes Care; 2018 Jun; 41(6):1227-1234. PubMed ID: 29650803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-utility of real-time continuous glucose monitoring versus self-monitoring of blood glucose in people with insulin-treated Type 2 diabetes in Canada.
    Alshannaq H; Isitt JJ; Pollock RF; Norman GJ; Cogswell G; Lynch PM; Roze S
    J Comp Eff Res; 2023 Oct; 12(10):e230075. PubMed ID: 37668608
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost-effectiveness of G5 Mobile continuous glucose monitoring device compared to self-monitoring of blood glucose alone for people with type 1 diabetes from the Canadian societal perspective.
    Chaugule S; Graham C
    J Med Econ; 2017 Nov; 20(11):1128-1135. PubMed ID: 28745578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness of a Real-Time Continuous Glucose Monitoring System Versus Self-Monitoring of Blood Glucose in People with Type 2 Diabetes on Insulin Therapy in the UK.
    Isitt JJ; Roze S; Sharland H; Cogswell G; Alshannaq H; Norman GJ; Lynch PM
    Diabetes Ther; 2022 Dec; 13(11-12):1875-1890. PubMed ID: 36258158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of a novel hybrid closed-loop system compared with continuous subcutaneous insulin infusion in people with type 1 diabetes in the UK.
    Roze S; Buompensiere MI; Ozdemir Z; de Portu S; Cohen O
    J Med Econ; 2021; 24(1):883-890. PubMed ID: 34098834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness Analysis of the MiniMed 670G Hybrid Closed-Loop System Versus Continuous Subcutaneous Insulin Infusion for Treatment of Type 1 Diabetes.
    Jendle J; Pöhlmann J; de Portu S; Smith-Palmer J; Roze S
    Diabetes Technol Ther; 2019 Mar; 21(3):110-118. PubMed ID: 30785311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated sensor-augmented pump therapy systems [the MiniMed® Paradigm™ Veo system and the Vibe™ and G4® PLATINUM CGM (continuous glucose monitoring) system] for managing blood glucose levels in type 1 diabetes: a systematic review and economic evaluation.
    Riemsma R; Corro Ramos I; Birnie R; Büyükkaramikli N; Armstrong N; Ryder S; Duffy S; Worthy G; Al M; Severens J; Kleijnen J
    Health Technol Assess; 2016 Feb; 20(17):v-xxxi, 1-251. PubMed ID: 26933827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term health economic benefits of sensor-augmented pump therapy vs continuous subcutaneous insulin infusion alone in type 1 diabetes: a U.K. perspective.
    Roze S; Smith-Palmer J; Valentine WJ; Cook M; Jethwa M; de Portu S; Pickup JC
    J Med Econ; 2016; 19(3):236-42. PubMed ID: 26510389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost implications of continuous glucose monitoring in pregnant women with type 1 diabetes in 3 Canadian provinces: a posthoc cost analysis of the CONCEPTT trial.
    Ahmed RJ; Gafni A; Hutton EK; Hu ZJ; Sanchez JJ; Murphy HR; Feig DS;
    CMAJ Open; 2021; 9(2):E627-E634. PubMed ID: 34088734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-utility analysis of Dexcom G6 real-time continuous glucose monitoring versus FreeStyle Libre 1 intermittently scanned continuous glucose monitoring in adults with type 1 diabetes in Belgium.
    Visser MM; Van Muylder A; Charleer S; Isitt JJ; Roze S; De Block C; Maes T; Vanhaverbeke G; Nobels F; Keymeulen B; Mathieu C; Luyten J; Gillard P; Verhaeghe N
    Diabetologia; 2024 Apr; 67(4):650-662. PubMed ID: 38236409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Cost-Effectiveness of Real-Time Continuous Glucose Monitoring (RT-CGM) in Type 2 Diabetes.
    Fonda SJ; Graham C; Munakata J; Powers JM; Price D; Vigersky RA
    J Diabetes Sci Technol; 2016 Jul; 10(4):898-904. PubMed ID: 26843480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of sensor-augmented pump therapy in two different patient populations with type 1 diabetes in Italy.
    Nicolucci A; Rossi MC; D'Ostilio D; Delbaere A; de Portu S; Roze S
    Nutr Metab Cardiovasc Dis; 2018 Jul; 28(7):707-715. PubMed ID: 29753586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of Initiating an Insulin Pump in T1D Adults Using Continuous Glucose Monitoring Compared with Multiple Daily Insulin Injections: The DIAMOND Randomized Trial.
    Wan W; Skandari MR; Minc A; Nathan AG; Zarei P; Winn AN; O'Grady M; Huang ES
    Med Decis Making; 2018 Nov; 38(8):942-953. PubMed ID: 30403576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of real-time continuous glucose monitoring in type 1 diabetes: a meta-analysis of randomized controlled trials.
    Dicembrini I; Cosentino C; Monami M; Mannucci E; Pala L
    Acta Diabetol; 2021 Apr; 58(4):401-410. PubMed ID: 32789691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.